Skip to main content
. 2022 Feb 1;132(3):e153604. doi: 10.1172/JCI153604

Figure 2. PD-1 antibody–armed laIL-2 has enhanced tumor control.

Figure 2

(A) A20 tumor-bearing mice (n = 5/group) were treated with equal molar amounts of Erb–laIL-2 (20 μg), anti–PD-1 (10 μg), or PD-1–laIL-2 (20 μg) on day 17. Tumor growth was assessed twice a week. (B) MC38 tumor-bearing mice (n = 5/group) were treated with equal molar amounts of Erb–laIL-2 (20 μg) and anti–PD-1 (10 μg) or PD-1–laIL-2 (20 μg) on day 21. Tumor growth was assessed twice a week. (C) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 or PD-1–wtIL-2 on day 17. Tumor growth was assessed twice a week. (D) A20 tumor-bearing mice (n = 5/group) were treated with equal molar amounts of Erb–laIL-2 (20 μg), anti–PD-L1 (10 μg), or PD-L1–laIL-2 (20 μg) on day 14. Tumor growth was assessed twice a week. (E) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg Erb–laIL-2, PD-L1–laIL-2, or PD-1–laIL-2 on day 14. Tumor growth was assessed twice a week. (F) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 and/or 100 μg anti–PD-L1 on day 20. Tumor growth was assessed twice a week. (G) A375 tumor-bearing humanized mice (n = 5/group) were treated with equal molar amounts of Erb–laIL-2 (20 μg) and anti–hPD-1 (10 μg) or hPD-1–laIL-2 (20 μg) on day 11. Tumor growth was assessed twice a week. Data represent mean ± SEM from 2 to 3 independent experiments. The P value was determined by 2-way ANOVA with Geisser-Greenhouse correction (A–G). **P < 0.01 and ****P < 0.0001.